Expanding cell analysis portfolio, Agilent acquires Luxcel Biosciences

The acquisition expands Agilent's portfolio with the addition of assay kits that are compatible with industry-standard plate readers.

Agilent Technologies (Santa Clara, CA) has acquired Luxcel Biosciences (Cork, Ireland), which develops real-time fluorescence plate-reader based in vitro cell assay kits. This acquisition expands Agilent's cell analysis portfolio with the addition of assay kits that are compatible with industry-standard plate readers.

Related: Entering Raman spectroscopy market, Agilent acquires Cobalt Light Systems

Luxcel is developing a portfolio of in vitro cell-based assay kits and solutions targeting cell metabolism, drug safety and toxicity, as well as hypoxia and oxidative stress for a variety of life science customers from research institutions to pharmaceutical companies. Scientists use this technology to understand the roll of cell metabolism across a variety of important research areas, including cancer, metabolic disorders, cardiovascular disease, immunology, and infectious disease.

Founded in 2002 by Richard Fernandes and Dmitri Papkovsky as a spinout company from University College Cork and a member of the High Potential Start Up program at Enterprise Ireland, Luxcel has 12 employees and is headquartered in Cork. The Luxcel team will remain in Cork and form a dedicated sensor chemistries and bioassay solutions group within Agilent's Cell Analysis Division. Financial terms of the deal are not being disclosed.

For more information, please visit www.agilent.com and www.luxcel.com.

More in Biophotonics Tools